BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $841,000 | +97.4% | 51,735 | +68.2% | 0.03% | +100.0% |
| Q4 2021 | $426,000 | -3.6% | 30,765 | 0.0% | 0.01% | -27.8% |
| Q3 2021 | $442,000 | -32.6% | 30,765 | -25.9% | 0.02% | -33.3% |
| Q2 2021 | $656,000 | +44.5% | 41,510 | -7.0% | 0.03% | +35.0% |
| Q1 2021 | $454,000 | -2.2% | 44,620 | -28.4% | 0.02% | -4.8% |
| Q4 2020 | $464,000 | +107.1% | 62,280 | -4.3% | 0.02% | +90.9% |
| Q3 2020 | $224,000 | – | 65,090 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 3,926,700 | $56,427,000 | 4.43% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $27,601,000 | 3.44% |
| HealthCor Management, L.P. | 3,849,470 | $55,317,000 | 2.39% |
| MPM BioImpact LLC | 704,767 | $10,128,000 | 1.57% |
| Baker Brothers Advisors | 12,710,818 | $182,654,000 | 0.80% |
| Bain Capital Public Equity Management II, LLC | 1,472,471 | $21,159,000 | 0.74% |
| Biondo Investment Advisors, LLC | 267,480 | $3,844,000 | 0.66% |
| North Star Investment Management Corp. | 442,900 | $6,364,000 | 0.52% |
| DOLIVER ADVISORS, LP | 100,000 | $1,437,000 | 0.48% |
| Lisanti Capital Growth, LLC | 219,450 | $3,153,000 | 0.46% |